Abstract
Liraglutide is a Glucagon like Peptide-1 (GLP-1) receptor agonist, which stimulates GLP-1 receptors and consequently leads to various cardio-metabolic and glycemic improvements in individuals with Type 2 Diabetes Mellitus (T2DM). It is administered once daily as a subcutaneous injection and has been extensively studied in randomized placebo and active comparator studies demonstrating favorable effects on glycemic control and weight reduction. This short review summarizes the role and practical use of this agent in the context of efficacy and safety information obtained during clinical trials.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Blood Glucose / drug effects
-
Blood Glucose / metabolism
-
Clinical Trials as Topic / methods
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / diagnosis
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Drug Evaluation / methods
-
Glucagon-Like Peptide 1 / analogs & derivatives*
-
Glucagon-Like Peptide 1 / pharmacology
-
Glucagon-Like Peptide 1 / therapeutic use
-
Glucagon-Like Peptide-1 Receptor
-
Humans
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use*
-
Liraglutide
-
Receptors, Glucagon / agonists
-
Treatment Outcome
Substances
-
Blood Glucose
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Hypoglycemic Agents
-
Receptors, Glucagon
-
Liraglutide
-
Glucagon-Like Peptide 1